» Articles » PMID: 33335100

Baseline Mapping of Severe Fever with Thrombocytopenia Syndrome Virology, Epidemiology and Vaccine Research and Development

Overview
Journal NPJ Vaccines
Date 2020 Dec 18
PMID 33335100
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Severe fever with thrombocytopenia syndrome virus (SFTSV) is a newly emergent tick-borne bunyavirus first discovered in 2009 in China. SFTSV is a growing public health problem that may become more prominent owing to multiple competent tick-vectors and the expansion of human populations in areas where the vectors are found. Although tick-vectors of SFTSV are found in a wide geographic area, SFTS cases have only been reported from China, South Korea, Vietnam, and Japan. Patients with SFTS often present with high fever, leukopenia, and thrombocytopenia, and in some cases, symptoms can progress to severe outcomes, including hemorrhagic disease. Reported SFTSV case fatality rates range from ~5 to >30% depending on the region surveyed, with more severe disease reported in older individuals. Currently, treatment options for this viral infection remain mostly supportive as there are no licensed vaccines available and research is in the discovery stage. Animal models for SFTSV appear to recapitulate many facets of human disease, although none of the models mirror all clinical manifestations. There are insufficient data available on basic immunologic responses, the immune correlate(s) of protection, and the determinants of severe disease by SFTSV and related viruses. Many aspects of SFTSV virology and epidemiology are not fully understood, including a detailed understanding of the annual numbers of cases and the vertebrate host of the virus, so additional research on this disease is essential towards the development of vaccines and therapeutics.

Citing Articles

Emerging Arboviral Diseases in Pakistan: Epidemiology and Public Health Implications.

Ammar M, Moaaz M, Yue C, Fang Y, Zhang Y, Shen S Viruses. 2025; 17(2).

PMID: 40006987 PMC: 11860545. DOI: 10.3390/v17020232.


Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus.

Hicks P, Manzoni T, Westover J, Petch R, Roper B, Gowen B Vaccines (Basel). 2025; 12(12.

PMID: 39772063 PMC: 11728676. DOI: 10.3390/vaccines12121403.


Limitations of a proper SFTSV mouse model using human C-type lectin receptors.

Kim Y, Ro H, Lee J, Song Y, Lee H, Cho N Front Microbiol. 2025; 15:1452739.

PMID: 39749135 PMC: 11693710. DOI: 10.3389/fmicb.2024.1452739.


N6-methyladenosine RNA modification promotes Severe Fever with Thrombocytopenia Syndrome Virus infection.

Chen Z, Zhang J, Wang J, Tong H, Pan W, Ma F PLoS Pathog. 2024; 20(11):e1012725.

PMID: 39585899 PMC: 11627400. DOI: 10.1371/journal.ppat.1012725.


Recent research advances in the development of Dabie Banda virus vaccines.

Yu C, Lin Y, Dai Y, Wu B, Qi Z, Qian X PLoS Negl Trop Dis. 2024; 18(8):e0012411.

PMID: 39207951 PMC: 11361446. DOI: 10.1371/journal.pntd.0012411.


References
1.
Liu W, Lu Q, Cui N, Li H, Wang L, Liu K . Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome. Clin Infect Dis. 2013; 57(9):1292-9. DOI: 10.1093/cid/cit530. View

2.
Takahashi T, Maeda K, Suzuki T, Ishido A, Shigeoka T, Tominaga T . The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis. 2013; 209(6):816-27. PMC: 7107388. DOI: 10.1093/infdis/jit603. View

3.
Hayasaka D, Shimada S, Aoki K, Takamatsu Y, Uchida L, Horio M . Epidemiological Survey of Severe Fever with Thrombocytopenia Syndrome Virus in Ticks in Nagasaki, Japan. Trop Med Health. 2015; 43(3):159-64. PMC: 4593780. DOI: 10.2149/tmh.2015-01. View

4.
Liu K, Cui N, Fang L, Wang B, Lu Q, Peng W . Epidemiologic features and environmental risk factors of severe fever with thrombocytopenia syndrome, Xinyang, China. PLoS Negl Trop Dis. 2014; 8(5):e2820. PMC: 4014392. DOI: 10.1371/journal.pntd.0002820. View

5.
Arikawa J, Schmaljohn A, Dalrymple J, Schmaljohn C . Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies. J Gen Virol. 1989; 70 ( Pt 3):615-24. DOI: 10.1099/0022-1317-70-3-615. View